ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Thollet, Aurélie ^a,b,c,d   Vendrell, Julie A ^a,b,c,d   Payen, Léa ^a,b,c,d   Ghayad, Sandra E ^a,b,c,d   Ben Larbi, Sabrina ^a,b   Grisard, Evelyne ^a,b,c,d   Collins, Colin ^e   Villedieu, Marie ^a,b,c,d   Cohen, Pascale A ^a,b,c,d  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c INSERM   (France)

^d CENTRE LÉON BÉRARD   (France)

^e VANCOUVER PROSTATE CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; GEMCITABINE; PACLITAXEL; PROTEIN BCL 2; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; AURKA PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; TRANSACTIVATOR PROTEIN; ZNF217 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CANCER THERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; DRUG EFFECT; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; PACLITAXEL; PROTEIN-SERINE-THREONINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANS-ACTIVATORS;

EID: 78049482204     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-291     Document Type: Article

References (44)

1. Quinlan KG, Verger A, Yaswen P, Crossley M. Amplification of zinc finger gene 217 (ZNF217) and cancer: when good fingers go bad. Biochim Biophys Acta 2007, 1775:333-340.
2. Sen S, Zhou H, White RA. A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 1997, 14:2195-2200. 10.1038/sj.onc.1201065, 9174055.
3. Lee JM. The role of protein elongation factor eEF1A2 in ovarian cancer. Reprod Biol Endocrinol 2003, 1:69. 10.1186/1477-7827-1-69, 239897, 14588074.
4. Collins C, Rommens JM, Kowbel D, Godfrey T, Tanner M, Hwang SI, Polikoff D, Nonet G, Cochran J, Myambo K, et al. Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci USA 1998, 95:8703-8708. 10.1073/pnas.95.15.8703, 21140, 9671742.
5. Ginestier C, Cervera N, Finetti P, Esteyries S, Esterni B, Adelaide J, Xerri L, Viens P, Jacquemier J, Charafe-Jauffret E, et al. Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clin Cancer Res 2006, 12:4533-4544. 10.1158/1078-0432.CCR-05-2339, 16899599.
6. Ginzinger DG, Godfrey TE, Nigro J, Moore DH, Suzuki S, Pallavicini MG, Gray JW, Jensen RH. Measurement of DNA copy number at microsatellite loci using quantitative PCR analysis. Cancer Res 2000, 60:5405-5409.
7. Nonet GH, Stampfer MR, Chin K, Gray JW, Collins CC, Yaswen P. The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells. Cancer Res 2001, 61:1250-1254.
8. Chin K, de Solorzano CO, Knowles D, Jones A, Chou W, Rodriguez EG, Kuo WL, Ljung BM, Chew K, Myambo K, et al. In situ analyses of genome instability in breast cancer. Nat Genet 2004, 36:984-988. 10.1038/ng1409, 15300252.
9. Li P, Maines-Bandiera S, Kuo WL, Guan Y, Sun Y, Hills M, Huang G, Collins CC, Leung PC, Gray JW, et al. Multiple roles of the candidate oncogene ZNF217 in ovarian epithelial neoplastic progression. Int J Cancer 2007, 120:1863-1873. 10.1002/ijc.22300, 17266044.
10. Collins C, Volik S, Kowbel D, Ginzinger D, Ylstra B, Cloutier T, Hawkins T, Predki P, Martin C, Wernick M, et al. Comprehensive genome sequence analysis of a breast cancer amplicon. Genome Res 2001, 11:1034-1042. 10.1101/gr.GR1743R, 311107, 11381030.
11. Banck MS, Li S, Nishio H, Wang C, Beutler AS, Walsh MJ. The ZNF217 oncogene is a candidate organizer of repressive histone modifiers. Epigenetics 2009, 4:100-106. 10.4161/epi.4.2.7953, 2929765, 19242095.
12. Cowger JJ, Zhao Q, Isovic M, Torchia J. Biochemical characterization of the zinc-finger protein 217 transcriptional repressor complex: identification of a ZNF217 consensus recognition sequence. Oncogene 2007, 26:3378-3386. 10.1038/sj.onc.1210126, 17130829.
13. Quinlan KG, Nardini M, Verger A, Francescato P, Yaswen P, Corda D, Bolognesi M, Crossley M. Specific recognition of ZNF217 and other zinc finger proteins at a surface groove of C-terminal binding proteins. Mol Cell Biol 2006, 26:8159-8172. 10.1128/MCB.00680-06, 1636751, 16940172.
14. Huang G, Krig S, Kowbel D, Xu H, Hyun B, Volik S, Feuerstein B, Mills GB, Stokoe D, Yaswen P, et al. ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction. Hum Mol Genet 2005, 14:3219-3225. 10.1093/hmg/ddi352, 16203743.
15. Sun G, Zhou J, Yin A, Ding Y, Zhong M. Silencing of ZNF217 gene influences the biological behavior of a human ovarian cancer cell line. Int J Oncol 2008, 32:1065-1071.
16. Sun Y, Wong N, Guan Y, Salamanca CM, Cheng JC, Lee JM, Gray JW, Auersperg N. The eukaryotic translation elongation factor eEF1A2 induces neoplastic properties and mediates tumorigenic effects of ZNF217 in precursor cells of human ovarian carcinomas. Int J Cancer 2008, 123:1761-1769. 10.1002/ijc.23708, 2606039, 18661515.
17. McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 2008, 1785:96-132.
18. Mackay A, Tamber N, Fenwick K, Iravani M, Grigoriadis A, Dexter T, Lord CJ, Reis-Filho JS, Ashworth A. A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines. Breast Cancer Res Treat 2009, 118:481-498. 10.1007/s10549-008-0296-7, 19169812.
19. Shadeo A, Lam WL. Comprehensive copy number profiles of breast cancer cell model genomes. Breast Cancer Res 2006, 8:R9. 10.1186/bcr1370, 1413994, 16417655.
20. Jang SH, Wientjes MG, Au JL. Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther 2001, 298:1236-1242.
21. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R. Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 2000, 58:624-632.
22. Shapiro AB, Ling V. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 1997, 250:130-137. 10.1111/j.1432-1033.1997.00130.x, 9432000.
23. Wang EJ, Casciano CN, Clement RP, Johnson WW. In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein. Drug Metab Dispos 2000, 28:522-528.
24. Wang EJ, Casciano CN, Clement RP, Johnson WW. Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun 2001, 289:580-585. 10.1006/bbrc.2001.6000, 11716514.
25. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002, 2:1-17. 10.2174/1568011023354290, 12678749.
26. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996, 56:816-825.
27. Kutuk O, Letai A. Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res 2008, 68:7985-7994. 10.1158/0008-5472.CAN-08-1418, 2603173, 18829556.
28. Noguchi S. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 2006, 97:813-820. 10.1111/j.1349-7006.2006.00265.x, 16805818.
29. Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003, 3:51-62. 10.1016/S1535-6108(02)00235-0, 12559175.
30. Blagosklonny MV. How cancer could be cured by 2015. Cell Cycle 2005, 4:269-278. 10.4161/cc.4.11.2208, 15655345.
31. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death. N Engl J Med 2009, 361:1570-1583. 10.1056/NEJMra0901217, 19828534.
32. Ibrado AM, Liu L, Bhalla K. Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells. Cancer Res 1997, 57:1109-1115.
33. Strobel T, Tai YT, Korsmeyer S, Cannistra SA. BAD partly reverses paclitaxel resistance in human ovarian cancer cells. Oncogene 1998, 17:2419-2427. 10.1038/sj.onc.1202180, 9824152.
34. Wang XX, Liu R, Jin SQ, Fan FY, Zhan QM. Overexpression of Aurora-A kinase promotes tumor cell proliferation and inhibits apoptosis in esophageal squamous cell carcinoma cell line. Cell Res 2006, 16:356-366. 10.1038/sj.cr.7310046, 16617331.
35. Yao JE, Yan M, Guan Z, Pan CB, Xia LP, Li CX, Wang LH, Long ZJ, Zhao Y, Li MW, et al. Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival. Mol Cancer 2009, 8:95. 10.1186/1476-4598-8-95, 2780390, 19891769.
36. Scharer CD, Laycock N, Osunkoya AO, Logani S, McDonald JF, Benigno BB, Moreno CS. Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells. J Transl Med 2008, 6:79. 10.1186/1479-5876-6-79, 2614415, 19077237.
37. Littlepage LE, Wu H, Andresson T, Deanehan JK, Amundadottir LT, Ruderman JV. Identification of phosphorylated residues that affect the activity of the mitotic kinase Aurora-A. Proc Natl Acad Sci USA 2002, 99:15440-15445. 10.1073/pnas.202606599, 137735, 12422018.
38. Castro A, Arlot-Bonnemains Y, Vigneron S, Labbe JC, Prigent C, Lorca T. APC/Fizzy-Related targets Aurora-A kinase for proteolysis. EMBO Rep 2002, 3:457-462. 10.1093/embo-reports/kvf095, 1084108, 11964384.
39. Littlepage LE, Ruderman JV. Identification of a new APC/C recognition domain, the A box, which is required for the Cdh1-dependent destruction of the kinase Aurora-A during mitotic exit. Genes Dev 2002, 16:2274-2285. 10.1101/gad.1007302, 186670, 12208850.
40. Fukuda T, Mishina Y, Walker MP, DiAugustine RP. Conditional transgenic system for mouse aurora a kinase: degradation by the ubiquitin proteasome pathway controls the level of the transgenic protein. Mol Cell Biol 2005, 25:5270-5281. 10.1128/MCB.25.12.5270-5281.2005, 1140609, 15923640.
41. Cha TL, Chuang MJ, Wu ST, Sun GH, Chang SY, Yu DS, Huang SM, Huan SK, Cheng TC, Chen TT, et al. Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. Clin Cancer Res 2009, 15:840-850. 10.1158/1078-0432.CCR-08-1918, 19188154.
42. Lim SK, Gopalan G. Aurora-A kinase interacting protein 1 (AURKAIP1) promotes Aurora-A degradation through an alternative ubiquitin-independent pathway. Biochem J 2007, 403:119-127. 10.1042/BJ20061272, 1828899, 17125467.
43. Vendrell JA, Magnino F, Danis E, Duchesne MJ, Pinloche S, Pons M, Birnbaum D, Nguyen C, Theillet C, Cohen PA. Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol 2004, 32:397-414. 10.1677/jme.0.0320397, 15072547.
44. Vendrell JA, Bieche I, Desmetz C, Badia E, Tozlu S, Nguyen C, Nicolas JC, Lidereau R, Cohen PA. Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines. Endocr Relat Cancer 2005, 12:75-92. 10.1677/erc.1.00899, 15788640.